HIV/AIDS HAART Adherence: HIV viral loads decrease following HAART adherence intervention program

AIDSWEEKLY Plus; Monday, June 5, 2006
Staff Medical Writers

According to recent research from Australia, "The aim was to analyze data from two randomized controlled trials (RCTs) to determine if an adherence intervention program for antiretroviral therapy (ART) resulted in a reduction in viral load.

"A cohort analysis of pre- and postintervention viral loads and CD4 counts using paired analysis was undertaken on participants who received the intervention program. Analysis was also undertaken on a control group."

"The intervention participants had an increase in mean CD4 count (450-478, p=0.26), and a decline in log viral load (2.48-2.36, p=0.056). The control group had a decline in mean CD4 counts (596-570, p=0.53), and an increase in log viral load (2.09-2.11, p=0.78)," A. Doxanakis and colleagues at Melbourne Sexual Health Center reported.

The authors concluded, "The use of an adherence intervention program is associated with a decrease in mean viral load, which is in contrast to the control group that demonstrated an increase in viral load over time."

Doxanakis and colleagues published their study in International Journal of STD & AIDS (Cohort analysis of two multidisciplined adherence intervention programs for patients on antiretroviral therapy. Int J STD AIDS. 2006 Apr;17(4):257-9).

For additional information, contact C.K. Fairley, Melbourne Sexual Health Center, 580 Swanston St., Melbourne, Vic 3053, Australia.

Publisher contact information for the International Journal of STD & AIDS is: Royal Society Medicine Press Ltd., 1 Wimpole Street, London W1G 0AE, England.

Keywords: Melbourne, Australia, HIV/AIDS, HAART, Adherence Intervention Program, Viral Load, CD4 Cell Count.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Doxanakis A, Read T, Levy R, et al., "Cohort analysis of two multidisciplined adherence intervention programmes for patients on antiretroviral therapy.", Int J STD AIDS. 2006 Apr;17(4):257-9.

PubMED Related articles Search

2006-06-05
AW060601

Copyright © 2006 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.